Search

Your search keyword '"Boni, Corrado"' showing total 202 results

Search Constraints

Start Over You searched for: Author "Boni, Corrado" Remove constraint Author: "Boni, Corrado"
202 results on '"Boni, Corrado"'

Search Results

1. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX

2. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial

3. Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study

4. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

7. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis

9. Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

11. Phase II, randomized trial of preoperative epirubicin-paclitaxel +/− gefitinib with biomarker evaluation in operable breast cancer

13. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer

14. Oxaliplatin, Fluorourcil, and Leucovorin as adjuvant treatment for Colon cancer

20. Phase III Study of Letrozole Versus Tamoxifen as First-Line Therapy of Advanced Breast Cancer in Postmenopausal Women: Analysis of Survival and Update of Efficacy From the International Letrozole Breast Cancer Group

21. A MULTISTEP RANDOMIZED PHASE II/III TRIAL COMPARING OXALIPLATIN (OXA)+ 5 FLUOROURACIL (FU) TO VINORELBINE (VIN)+FU (FUN) AFTER TAXANE (T)/ANTHRACYCLINE (A) FAILURE IN ADVANCED/METASTATIC BREAST CANCER (MBC) PATIENTS (PTS): 245

23. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma

24. Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer Group

25. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen

27. Randomized Trial of Fenretinide to Prevent Second Breast Malignancy in Women With Early Breast Cancer

28. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study

29. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

30. Early tumor shrinkage (ETS) and deepness of response (DoR) to predict progression-free, postprogression, and overall survival: Results from the phase III TRIBE trial

31. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX

32. HER2-amplification level and tumor-infiltrating lymphocytes in breast cancer patients treated with neoadjuvant trastuzumab.

33. Diamond: immunohistochemistry versus sequencing in EGFR analysis of lung adenocarcinomas

34. Relationship between levels of HER-2 amplification and pathologic complete response to trastuzumab-based neoadjuvant treatment.

36. Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset

37. Refining sorafenib therapy: lessons from clinical practice

38. FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (mCRC): Updated survival results of the phase III TRIBE trial by the GONO group.

40. Subgroup analyses in RAS mutant, BRAF mutant and all-wt mCRC pts treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study.

41. Safety and tolerability of regorafenib (REG) in Italian patients: Subgroup analysis of the phase III CORRECT study in metastatic colorectal cancer (mCRC).

42. Diamond project: Immunohistochemical screening using EGFR mutation-specific antibodies in lung adenocarcinomas.

43. Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase IIB Neoadjuvant Study of Letrozole-Lapatinib in Postmenopausal Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, Operable Breast Cancer

44. Early tumor shrinkage (ETS) and deepness of response (DoR) to predict progression-free, postprogression, and overall survival: Results from the phase III TRIBE trial.

45. Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: The need for further revision of dose and schedule

46. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial

47. Bevacizumab Beyond Progression in Metastatic Colorectal Cancer Patients Receiving a First-Line Treatment Containing Bevacizumab: Update of Bebyp Trial by Gono

48. Preoperative letrozole plus lapatinib/placebo for HR+/HER2 negative operable breast cancer: Biomarker analyses of the randomized phase II LET-LOB study.

49. Second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) who progressed to a first-line treatment containing BV: Updated results of the phase III “BEBYP” trial by the Gruppo Oncologico Nord Ovest (GONO).

50. FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group.

Catalog

Books, media, physical & digital resources